Nichole Smith, MD
Endocrinology, Diabetes & Metabolism · Merriam, KSNPI 1770846685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 551 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,197 and has fallen 68.9% since, to $682 in 2025.
Across 551 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$788
- AstraZeneca$731
- Abbott$720
- Boehringer Ingelheim$686
- Corcept Therapeutics$436
- plus $4K from 34 others
What the payments were for
- Food & beverage$9,436100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$108
How this compares
$9,442 in reported general payments places this provider in the 80th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 198 | $288,553 |
| JardianceEmpagliflozin | 155 | $184,246 |
| MounjaroTirzepatide | 106 | $154,481 |
| TrulicityDulaglutide | 82 | $138,446 |
| TymlosAbaloparatide | 50 | $137,325 |
| ProliaDenosumab | 67 | $117,045 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $63,977 |
| JanuviaSitagliptin Phosphate | 54 | $63,238 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $57,921 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $47,261 |
| RybelsusSemaglutide | 26 | $42,779 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 33 | $31,602 |
| FarxigaDapagliflozin Propanediol | 30 | $31,248 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $28,721 |
| Humalog Kwikpen U-100Insulin Lispro | 47 | $28,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $788 | $336,093247 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,644 | $292,927188 claims |
| Boehringer IngelheimJardiance, Tradjenta | $686 | $200,283168 claims |
| Radius Health, Inc.Tymlos | $347 | $137,32550 claims |
| AmgenProlia | $360 | $117,04567 claims |
| MerckJanuvia | $197 | $63,23854 claims |
| AstraZenecaFarxiga | $731 | $31,24830 claims |
| Johnson & JohnsonInvokana | $11 | $15,40120 claims |
| AbbVieSynthroid | $436 | $9,179107 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $291 | $3,345425 claims |
| Sanofi-aventis U.S. LLCLantus | $407 | $2,87926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Merriam
- Lisa HaysMerriam$4K
- Sabah PatelMerriam$904
- Dany ZayourWichita$744K
- Andrew GreenShawnee Mission$322K
- Michael SokolOverland Park$227K
- Rami MortadaWichita$105K
- Sajeev MenonOverland Park$25K
- Georges ElhomsyWichita$14K
- Richard GomendozaSalina$13K
- John MilesKansas City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.